Cardiovascular Considerations in Hematopoietic Stem Cell Transplantation , 1st ed. 2024
Langue : Anglais
Coordonnateurs : Alizadehasl Azin, Ghavamzadeh Ardeshir, Emami Amir Hossein, Janbabaei Ghasem, Khoda-Amorzideh Davood
This book discusses the epidemiology and the known cardiotoxic effects of chemoradiation agents in addition to newer therapies in hematopoietic stem cell transplantation (HSCT). Recent expert consensus statements from cardiology and hematology/oncology societies are reviewed in regard to risk stratification of the patient based on the type of treatments they are undergoing. Finally, gaps in knowledge are identified with proposed avenues of research that allow for more accurate risk assessment, prediction and potential treatment of the HSCT patient in attenuating the risk of developing cardiovascular comorbidities.
HSCT at a glance.- Burden of cardiovascular disease in HSCT.- Risk factors and Mechanisms of Cardiotoxicity in HSCT.- Cardiotoxicity of commonly used drugs in HSCT.- Pre-HSCT cardiovascular evaluation.- HSCT in low EF patients.- Arrhythmias and conduction disorders in HSCT.- Coronary and peripheral arterial disease in HSCT.- Thrombotic disease in HSCT.- Pulmonary hypertension in HSCT.- Pericardial disease in HSCT.- Metabolic syndrome in HSCT.- HSCT in patients with cardiac amyloidosis.- HSCT in patients with autoimmune conditions, sickle cell anaemia and thalassemia.- Cardiotoxicity surveillance and cardioprotective strategies in HSCT.
Dr. Azin Alizadehasl, a cardio-oncologist and echocardiologist, stands as the head and founder of the first cardio-oncology ward and research center at Rajaei Heart Institute in Iran. Currently serving as the assistant professor at Rajaei Heart Institute, she embarked on her medical degree as the first rank student and expanding her knowledge through diverse courses in the USA and Canada, Dr. Alizadehasl has achieved noteworthy distinctions, including the Fellowship of the American Society of Echocardiography (FASE) and the Fellowship of the American College of Cardiology (FACC).
Professor Ardeshir Ghavamzadeh is widely recognized as the pioneer of hemato-oncology in Iran. He holds the distinction of being the first individual to perform a Bone Marrow Transplant (BMT) in the country. In recognition of his exceptional contributions, he was honored with the prestigious CIBMTR Distinguished Service Award in 2012.
Dr. Amirhossein Emami is an assistant professor of hemato-oncology at Tehran University of Medical Sciences, currently he is the head of hemato-oncology and stem cell transplantation ward of Imam Khomeini Hospital of Tehran. He has previously held the position of head of Tehran Medical School. He was bestowed with the prestigious "Medical Education Award" in 2011. His primary area of expertise revolves around advancing oncology care by fostering the growth of multi-disciplinary teams, with a specific focus on colorectal malignancies
Dr. Ghasem Janbabaei is a hemato-oncologist at Tehran University of Medical Science. He has achieved the 3rd rank in the board certification of Internal Medicine in Iran. He has previously served as the head of the Deputy of Medical Affairs at the Ministry of Health in Iran and has authored approximately 200 articles in the field of oncology.
Dr. Davood Khoda-Amorzideh is a cardiologist and the first gr
Describes a framework for the cardiovascular evaluation and management of patients undergoing HSCT
Reveals the pathophysiology of HSCT, emphasizing therapeutic exposures and comorbidities
Reviews existing cardiology and hematology/oncology guidleines to identify patients able to tolerate HSCT
Date de parution : 05-2024
Ouvrage de 329 p.
15.5x23.5 cm
Thèmes de Cardiovascular Considerations in Hematopoietic Stem Cell... :
© 2024 LAVOISIER S.A.S.
